Title: 
Official Title: To amend title XI of the Social Security Act to require pharmaceutical and
            device manufacturers to publicly disclose covered payments made to patient advocacy
            organizations.
Number of Sections: 2
Source: versions - Introduced in Senate
Media Type: text/xml

================================================================================

Section 1:
1.
            Short title
 This Act may be cited as the Open Payments Expansion Act.

Section 2:
2.
            Disclosure of pharmaceutical and device manufacturer covered payments to patient
                advocacy organizations
            
                (a)
                In general
 Section 1128G of the Social Security Act (42 U.S.C. 1320a–7h) is amended—
                
                    (1)
 in subsection (a), by adding at the end the following new paragraph:
                    
                        
                            (3)
                            Donations to patient advocacy organizations
                            
                                (A)
                                In general
 In addition to the requirements under paragraphs (1) and (2), on March 31, 2027, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, details regarding any covered payment made by such manufacturer or organization to any patient advocacy organization, including—
                                
                                    (i)
 the name of the patient advocacy organization; and   (ii) the amount of the covered payment.
                                
                            
                            
                                (B)
                                Definitions
 In this paragraph:  (i) Covered payment The term covered payment means any—
                                    
                                        (I)
 payment or other transfer of value; or 
                                    
                                    
                                        (II)
 indirect payment or other transfer of value.
                                    
                                
                                
                                    (ii)
                                    Indirect payment or
                                        other transfer of value
 The term indirect payment or other transfer of value means a payment or other transfer of value made by an applicable manufacturer or applicable group purchasing organization to a patient advocacy organization through a third party, where the applicable manufacturer or applicable group purchasing organization requires, instructs, directs, or otherwise causes the third party to provide the payment or transfer of value, in whole or in part, to a patient advocacy organization.
                                
                                
                                    (iii)
                                    Patient advocacy
                                        organization
 The term patient advocacy organization means an organization described in section 501(c)(3) of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code that—
                                    
                                        (I)
 provides education, advocacy, and support services oriented towards patients and caregivers;
                                    
                                    
                                        (II)
 is concerned with a medical condition diagnosed by a licensed medical practitioner who is in good standing with a State licensing body; or
                                    
                                    
                                        (III)
 has a mission that seeks to help vulnerable individuals affected by medical conditions or to help the families of such vulnerable individuals and takes actions consistent with such mission.
                                    
                                
                            
                        
                        ; and
                    
                
                
                    (2)
 in subsection (c)(1)(C)(ix), by striking or covered recipient each place it appears and inserting covered recipient, or patient advocacy organization.
                
            
            
                (b)
                Administration
 Chapter 35 of title 44, United States Code, shall not apply to this section or the amendments made by this section.


================================================================================

Raw Text:
119 S2710 IS: Open Payments Expansion Act
U.S. Senate
2025-09-04
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.



        II
        119th CONGRESS
        1st Session
        S. 2710
        IN THE SENATE OF THE UNITED STATES
        
            September 4, 2025
            Mr. Grassley (for himself and Ms. Hassan) introduced the following bill; which was
                read twice and referred to the Committee on
                    Finance
        
        A BILL
        To amend title XI of the Social Security Act to require pharmaceutical and
            device manufacturers to publicly disclose covered payments made to patient advocacy
            organizations.
    
    
        
            1.
            Short title
 This Act may be cited as the Open Payments Expansion Act.
        
        
            2.
            Disclosure of pharmaceutical and device manufacturer covered payments to patient
                advocacy organizations
            
                (a)
                In general
 Section 1128G of the Social Security Act (42 U.S.C. 1320a–7h) is amended—
                
                    (1)
 in subsection (a), by adding at the end the following new paragraph:
                    
                        
                            (3)
                            Donations to patient advocacy organizations
                            
                                (A)
                                In general
 In addition to the requirements under paragraphs (1) and (2), on March 31, 2027, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, details regarding any covered payment made by such manufacturer or organization to any patient advocacy organization, including—
                                
                                    (i)
 the name of the patient advocacy organization; and   (ii) the amount of the covered payment.
                                
                            
                            
                                (B)
                                Definitions
 In this paragraph:  (i) Covered payment The term covered payment means any—
                                    
                                        (I)
 payment or other transfer of value; or 
                                    
                                    
                                        (II)
 indirect payment or other transfer of value.
                                    
                                
                                
                                    (ii)
                                    Indirect payment or
                                        other transfer of value
 The term indirect payment or other transfer of value means a payment or other transfer of value made by an applicable manufacturer or applicable group purchasing organization to a patient advocacy organization through a third party, where the applicable manufacturer or applicable group purchasing organization requires, instructs, directs, or otherwise causes the third party to provide the payment or transfer of value, in whole or in part, to a patient advocacy organization.
                                
                                
                                    (iii)
                                    Patient advocacy
                                        organization
 The term patient advocacy organization means an organization described in section 501(c)(3) of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code that—
                                    
                                        (I)
 provides education, advocacy, and support services oriented towards patients and caregivers;
                                    
                                    
                                        (II)
 is concerned with a medical condition diagnosed by a licensed medical practitioner who is in good standing with a State licensing body; or
                                    
                                    
                                        (III)
 has a mission that seeks to help vulnerable individuals affected by medical conditions or to help the families of such vulnerable individuals and takes actions consistent with such mission.
                                    
                                
                            
                        
                        ; and
                    
                
                
                    (2)
 in subsection (c)(1)(C)(ix), by striking or covered recipient each place it appears and inserting covered recipient, or patient advocacy organization.
                
            
            
                (b)
                Administration
 Chapter 35 of title 44, United States Code, shall not apply to this section or the amendments made by this section.